Jaguar Health, Inc. Stock News

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow tr...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted stock units (RSUs) to New Employee 1, 3,600 RSUs to New Employee 2, 600 RSUs to New Employee 3, 100 RSUs to New Employee 4, 600 RSUs to New Employee 5, and 600 RSUs to New Employee 6. The R...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement. Jaguar's president and chief executive officer Lisa Conte, as well as other members of the Company's board of directors and other C-suite and senior executives of Jaguar along with selected insti...

Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Investor Webcast. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the c...

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenu...

Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need SAN FRANCISCO, CA / ACCESS Newswire / March 28, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar An...

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant...

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference Click here to register for Jaguar's March 31 investor webcast Company plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024 SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the c...